Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Pharmaceutical
CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability
Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced